fig3

Strategies to combat cancer drug resistance: focus on copper metabolism and cuproptosis

Figure 3. The mechanism of cuproptosis. Copper ionophore elesclomol directly transports Cu2+ into cells and then Cu2+ is reduced to Cu+ via FDX1. After the reduction of Cu2+ into Cu+ via STEAP, Cu+ is pumped into cells via SLC31A1. FDX1 and LIAS induce DLAT lipoylation and aggregation, inducing the damage of the TCA cycle. As such, cells are dead via cuproptosis. FDX1: Ferredoxin 1; STEAP: 6-transmembrane epithelial antigen of prostate, comprises STEAP1, STEAP2, STEAP3, and STEAP4; SLC31A1: solute carrier family 31 member 1; LIAS: lipoic acid synthetase; DLAT: dihydrolipoamide S-acetyltransferase; TCA: tricarboxylic acid; LA: lipoic acid.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/